{"filings":[{"id":2088601,"accession_number":"0001104659-26-091671","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2026-08-06T12:05:35+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Q2 net loss $57.3M; completes sevasemten sale to Servier for up to $2.65B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $57.3M ($0.53/share) vs $36.1M ($0.34) in Q2 2025; R&D $47.5M, G&A $14.4M.","Completed sale of sevasemten and muscular dystrophy business to Servier for $1.55B upfront + up to $1.1B milestones (closed July 2026).","Cash $460.7M at June 30; pro forma $2.01B after sale proceeds (pre-tax/transaction costs).","Positive top-line Phase 2 CIRRUS-HCM data for EDG-7500 in HCM; Phase 3 expected Q4 2026.","EDG-15400 Phase 1 completed; Phase 2 in HFpEF expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1674077,"accession_number":"0001104659-26-084088","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K/A","filed_at":"2026-07-16T12:01:18+00:00","items":["9.01"],"status":"ready","headline":"Edgewise closes $1.55B sale of sevasemten to Servier; pivots to cardiovascular pipeline","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Received $1.55B upfront cash; eligible for up to $1.1B in regulatory/commercial milestones.","Pro forma cash at March 31, 2026: $1.53B (up from $33.2M historical).","Pro forma net income for FY2025: $1.1355B (vs. historical net loss of $167.8M).","Company now focused on cardiovascular assets EDG-7500, EDG-15400, and EDG-003.","Transition Services Agreement with Servier: at least 18 months; $17.9M deferred liability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1592557,"accession_number":"0001104659-26-082902","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2026-07-13T12:37:12+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Edgewise completes $1.55B sale of muscular dystrophy program to Servier; up to $2.65B total","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold sevasemten and muscular dystrophy program to Servier for $1.55B upfront plus up to $1.1B in milestones ($2.65B total).","Company refocuses on cardiovascular pipeline: EDG-7500 (HCM), EDG-15400 (HFpEF), and EDG-003 (undisclosed).","Upfront proceeds expected to fully fund EDG-7500 development through potential approval.","Plans to initiate Phase 3 trial for EDG-7500 in Q4 2026 and Phase 2 trial for EDG-15400 in HFpEF.","Core muscular dystrophy employees offered positions at Servier to ensure continuity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":889276,"accession_number":"0001104659-26-071011","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2026-06-05T20:33:33+00:00","items":["5.07"],"status":"ready","headline":"Edgewise Therapeutics stockholders elect three directors, ratify auditor, approve say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Laura Brege (87.3M for), Badreddin Edris (64.1M for), Jonathan Root (59.2M for) elected Class II directors.","KPMG LLP ratified as independent auditor for FY2026 with 99.6M for, 1.1K against, 578K abstain.","Say-on-pay advisory vote approved: 87.1M for, 3.5M against, 577K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":760117,"accession_number":"0001193125-26-249951","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2026-06-01T12:51:21+00:00","items":["1.01","9.01"],"status":"ready","headline":"Edgewise sells sevasemten to Servier for $1.55B upfront, plus up to $1.1B milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["$1.55B upfront cash; potential $1.1B in regulatory and commercial milestones totaling up to $2.65B.","Edgewise to focus on cardiovascular pipeline (EDG-7500, EDG-15400, EDG-003).","Upfront proceeds fully fund EDG-7500 development through potential approval.","On track to report 12-week CIRRUS-HCM Part D data in Q2 2026.","Transaction expected to close Q3 2026, subject to HSR and customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94885,"accession_number":"0001104659-26-056783","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Q1 net loss $49M, cash $499.6M; sevasemten Becker data up to 3.5 years","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $49.0M ($0.46/share) in Q1 2026 vs $40.8M ($0.43/share) in Q1 2025; cash and equivalents $499.6M.","R&D expense $42.7M (up 16% YoY) driven by EDG-7500 and EDG-15400 clinical activity, partly offset by lower sevasemten costs.","Long-term MESA OLE data shows sevasemten stabilizes function in Becker up to 3.5 years; 99% enrollment from prior trials.","Pivotal GRAND CANYON sevasemten top-line results expected Q4 2026; marketing application planned H1 2027.","CIRRUS-HCM Part D (EDG-7500) 12-week data in HCM expected Q2 2026; Phase 3 initiation H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107579,"accession_number":"0001104659-26-020108","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise reports Q4 net loss $50.2M ($0.47/sh); cash $530M; key trial readouts in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2025 was $50.2M ($0.47/sh) vs $40.7M ($0.39/sh) in prior quarter; no revenue.","Cash, cash equivalents and marketable securities total $530.1M as of Dec 31, 2025.","GRAND CANYON top-line results for sevasemten in Becker expected Q4 2026; NDA submission H1 2027.","CIRRUS-HCM Part D 12-week data for EDG-7500 in HCM expected H1 2026; Phase 3 start H2 2026.","EDG-15400 Phase 1 healthy adult data H1 2026; Phase 2 in HFpEF planned H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123938,"accession_number":"0001104659-25-114660","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Edgewise Therapeutics appoints Christopher Martin to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Martin, former CCO of Verona Pharma (acquired by Merck for ~$10B), joins as Class I director.","Appointment effective November 19, 2025; term expires at 2028 annual meeting.","Receives $40k annual cash retainer and ~$700k stock option grant (monthly vest over 3 years).","Board cites Martin's commercial launch expertise as critical for Becker MD launch and CV Phase 3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123937,"accession_number":"0001104659-25-109295","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Edgewise Therapeutics appoints Michael Nofi as CFO, succeeding retiring CFO Carruthers","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Nofi appointed CFO effective Nov 10, 2025; replaces R. Michael Carruthers who retired.","Nofi's annual base salary: $465,000, target cash bonus 40% of salary, plus stock option for 262,500 shares and 43,750 RSUs.","Carruthers to remain employee until Jan 31, 2026, then consultant through Oct 31, 2026, with continued equity vesting.","Nofi previously Chief Accounting Officer at SpringWorks Therapeutics; brings 30+ years life sciences finance experience.","No disagreement between Carruthers and company; transition supports Edgewise's late-stage clinical and commercialization prep."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123936,"accession_number":"0001104659-25-107419","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Q3 net loss $40.7M ($0.39/sh); cash $563.3M; GRAND CANYON data Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $563.3M at Sep 30, 2025.","R&D expense $37.5M (up $3.9M QoQ) driven by EDG-15400 Phase 1 start and CIRRUS-HCM activity.","Net loss $40.7M ($0.39 per share) vs $36.1M ($0.34) prior quarter.","GRAND CANYON pivotal Becker cohort (175 enrolled) on track for topline readout in Q4 2026.","EDG-7500 CIRRUS-HCM program update expected Q4 2025; EDG-15400 Phase 1 data H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140600,"accession_number":"0001104659-25-074987","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Q2 net loss $36.1M; positive sevasemten data in Becker, Duchenne","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $36.1M ($0.34/share) for Q2 2025; cash and equivalents $594M as of June 30.","MESA trial data: 99% enrollment; NSAA scores stable over 18 months in Becker participants.","Phase 2 LYNX/FOX trials in Duchenne identify 10 mg sevasemten dose for Phase 3; FDA meeting planned Q4 2025.","CIRRUS-HCM (EDG-7500) trial advancing; Part D enrolling; update expected Q4 2025.","GRAND CANYON pivotal trial in Becker fully enrolled; topline data expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158313,"accession_number":"0001104659-25-063028","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Edgewise announces positive sevasemten data; FDA provides clear path to first Becker therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MESA OLE: 99% enrollment (85 participants); NSAA scores improved 0.8 pts over 18 months, diverging from natural history declines.","FDA Type C: NSAA endorsed for traditional approval; CANYON alone insufficient; GRAND CANYON may serve as single pivotal study.","GRAND CANYON on track for topline data Q4 2026; highly powered to show NSAA difference vs placebo over 18 months.","Duchenne Phase 2 LYNX/FOX: 10 mg dose selected for Phase 3; well-tolerated; FOX suggests slower decline in post-gene therapy patients.","Plans to meet FDA Q4 2025 for Phase 3 Duchenne design; pivotal study initiation expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158312,"accession_number":"0001104659-25-045896","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Q1 net loss $40.8M; positive Phase 2 HCM data and $188M offering highlighted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Positive top-line data from Phase 2 CIRRUS-HCM: EDG-7500 reduced LVOT-G without meaningful LVEF changes; improved KCCQ and NT-proBNP.","Raised $188M net in April 2025 public offering; pro-forma cash exceeds $624M as of close.","Q1 2025 net loss of $40.8M ($0.43 loss/share); R&D expense $36.8M, G&A stable at $9.2M.","Sevasemten Phase 2 LYNX/FOX Duchenne data expected Q2 2025; Part D CIRRUS-HCM data due H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158311,"accession_number":"0001104659-25-030870","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Edgewise Therapeutics prices $200M common stock offering at $20.13 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["9,935,419 shares priced at $20.13; gross proceeds ~$200M before discounts and expenses.","Closing expected April 3, 2025; anticipated cash runway through 2028 (including existing cash).","Proceeds to fund sevasemten for Becker/Duchenne MD, EDG-7500 HCM trials, and R&D.","Participants include Braidwell, Cormorant, Driehaus, Invus, Janus, MPM, OrbiMed, Paradigm, Perceptive, RA Capital, Sofinnova.","Underwritten by Leerink, Piper Sandler, Guggenheim, and Truist Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158310,"accession_number":"0001104659-25-030839","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Edgewise reports positive Phase 2 data for EDG-7500 in HCM; 71% LVOT-G reduction at rest","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Obstructive HCM: 100 mg dose achieved mean 71% reduction in resting LVOT-G and 58% in provokable gradients over 4 weeks.","NT-proBNP reduced 62% in obstructive and 42% in nonobstructive HCM at 100 mg; KCCQ-OSS improved 23 and 17 points respectively.","No LVEF <50%; two participants had serious AF requiring cardioversion; one discontinuation due to dizziness.","Part D 12-week data expected H2 2025; Phase 3 CIRRUS-HCM trial initiation planned for H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176688,"accession_number":"0001104659-25-019498","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Therapeutics reports Q4 2024 net loss of $39.7M; pipeline milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $39.7M ($0.42 per share) for Q4 2024; cash and equivalents $470.2M as of Dec 31, 2024.","Completed GRAND CANYON enrollment (175 adults) for sevasemten in Becker; topline data expected Q4 2026.","Positive Phase 2 CANYON topline results for sevasemten in Becker; plan to discuss FDA filing in H1 2025.","On track to report CIRRUS-HCM Phase 2 data in Q1 2025 and LYNX/FOX Duchenne data in H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176687,"accession_number":"0001104659-25-005075","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Edgewise Therapeutics promotes Behrad Derakhshan to COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Behrad Derakhshan, Ph.D., appointed Chief Operating Officer effective January 8, 2025.","Previously served as Chief Business Officer since September 2020.","Annual base salary increased from $478,400 to $520,000; target bonus raised to 45%.","No family relationships with any director or executive officer of the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193526,"accession_number":"0001104659-24-129001","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Edgewise Phase 2 CANYON trial meets primary endpoint; sevasemten reduces CK by 28% in Becker muscular dystrophy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: CK decreased 28% vs placebo over months 6-12 in adults (p=0.02).","Key secondary NSAA showed 1.1-point trend favoring sevasemten (p=0.16); treatment group had more advanced disease at baseline.","TNNI2 biomarker reduced 77% vs placebo (p<0.001); functional tests (10-m walk, stair climb, 100-m) trended positive.","Sevasemten well-tolerated; no new safety concerns in adults or adolescents.","GRAND CANYON pivotal cohort enrollment on track for Q1 2025; 99% of eligible patients entered open-label extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193525,"accession_number":"0001104659-24-115077","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Q3 net loss $34.1M; Phase 2 CANYON data on track for Dec 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $34.1M ($0.36 per share) vs $31.5M ($0.34) prior quarter; cash $492.5M.","R&D expenses $32.2M (up $1.5M QoQ); G&A $8.2M (up $0.8M QoQ).","Top-line CANYON (Becker) data expected December 2024; EDG-7500 28-day data Q1 2025.","CIRRUS-HCM single dose: 67% mean reduction in resting LVOT gradient; no meaningful LVEF change.","LYNX (Duchenne) data due Q4 2024; FOX trial over-enrolled within two months."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209832,"accession_number":"0001104659-24-088426","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Edgewise Therapeutics adopts 2024 Inducement Plan, reserving 2M shares for new hires","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted 2024 Inducement Equity Incentive Plan effective August 10, 2024, reserving 2,000,000 shares of common stock.","Plan allows grants of nonstatutory stock options, SARs, restricted stock, RSUs, and performance awards as hiring inducements.","Adopted without stockholder approval under Nasdaq Listing Rule 5635(c)(4) – limited to new employees or merger hires.","Terms are substantially similar to the 2021 Equity Incentive Plan; no Exchange Program is permitted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209831,"accession_number":"0001104659-24-087031","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Therapeutics Q2 2024 net loss $31.5M; cash $511.8M; EDG-7500 Phase 1 complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $31.5M ($0.34 per share) vs $28.5M in prior quarter; no product revenue.","Cash and marketable securities $511.8M as of June 30, 2024.","Completed Phase 1 SAD/MAD trial of EDG-7500 in healthy volunteers; Phase 2 CIRRUS-HCM enrolling.","Sevasemten: CANYON Phase 2 data in Becker expected Q4 2024; GRAND CANYON pivotal cohort ongoing.","LYNX Phase 2 in Duchenne data expected Q4 2024; Phase 3 planned H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228033,"accession_number":"0001104659-24-070114","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Edgewise shareholders elect directors, ratify KPMG, approve officer exculpation charter amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class III directors Thompson, Koch, and Fox with 65M–75M shares For vs 6.9M–17.3M Against; broker non-votes 8.2M.","Ratified KPMG LLP as independent auditor for FY 2024: 90.5M For, 4K Against, 35K Abstain.","Approved certificate amendment to limit officer liability per Delaware law: 81.4M For, 938K Against, 1.4K Abstain; broker non-votes 8.2M.","Amendment to Article IX of the certificate of incorporation was filed on June 10, 2024, effective upon filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228032,"accession_number":"0001104659-24-059674","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Edgewise Therapeutics enters $175M ATM equity offering with Leerink Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Sales Agreement with Leerink Partners for at-the-market offering of up to $175M common stock.","Prior $125M ATM program with BofA Securities terminated on May 10, 2024.","Leerink will receive up to 3% commission on gross proceeds from shares sold.","Company has no obligation to sell shares and may suspend or terminate the program at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228031,"accession_number":"0001104659-24-059136","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Q1 net loss $28.5M; sevasemten shows positive Becker data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $532.8M as of March 31, 2024.","Net loss $28.5M ($0.33 per share) vs $30.1M ($0.47) prior quarter.","Sevasemten ARCH 2-year: NSAA stabilized, CK and TNNI2 decreased; DUNE showed 45% CK reduction vs placebo.","GRAND CANYON pivotal cohort recruiting ~120 patients with Becker; data expected Q4 2024.","EDG-7500 Phase 2 CIRRUS-HCM trial initiated; first patient dosed April 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228030,"accession_number":"0001104659-24-057783","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Edgewise Therapeutics appoints Arlene Morris to Board of Directors, effective May 6, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Morris replaces Peter Thompson on the Audit and Compensation Committees.","She brings 30+ years of biotech leadership, including CEO roles at Syndax and Affymax.","Annual cash retainer of $40,000 plus $7,500 for Audit and $5,000 for Compensation Committee service.","New director stock option grant with ~$500,000 fair value, vesting monthly over 3 years.","Appointment fills vacancy left by Kenneth Harrison's resignation in June 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246796,"accession_number":"0001104659-24-026336","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise posts Q4 net loss $0.47/sh; pro-forma cash >$550M; multiple trial readouts in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2023 was $30.1M ($0.47 per share), up from $25.7M ($0.41) in Q3 2023.","Cash, equivalents and marketable securities $318.4M at Dec 31, 2023; pro-forma >$550M after $231.8M net Jan 2024 offering.","R&D expenses $27.7M (+$3.9M QoQ); G&A $6.2M (+$0.5M QoQ) as clinical programs advanced.","Expect CANYON (Becker) data Q4 2024; ARCH 24-month, DUNE, and LYNX dose data in Q2 2024.","EDG-7500 Phase 1 data and Phase 2 obstructive HCM data expected Q3 2024; FOX trial dosing starts early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246795,"accession_number":"0001104659-24-005031","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Edgewise Therapeutics announces $240M underwritten offering of 21.8M shares at $11.00 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$240M from offering of 21.8M shares at $11.00; closing expected Jan 23, 2024.","Proceeds to fund potential U.S. commercial launch of EDG-5506 in Becker MD, Phase 3 in Duchenne, Phase 2 trials of EDG-7500 in hypertrophic cardiomyopathy.","New investors include RA Capital, TCGX, Venrock; existing investors Cormorant, Deerfield, Frazier, Janus, Novo, Orbimed, Perceptive, Surveyor.","Combined cash, equivalents, and proceeds expected to exceed $500M, funding operations into 2027.","Leerink Partners and Wedbush PacGrow acted as joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246794,"accession_number":"0001104659-24-004966","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Edgewise reports $318.4M cash, outlines 2024 milestones, terminates ATM program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents and marketable securities of $318.4M as of Dec 31, 2023; shares outstanding 70.5M.","EDG-5506: 24-month ARCH data (Becker MD) in H1 2024; 1-year CANYON data in Q4 2024.","EDG-5506: Phase 2 DUNE exercise data (Becker, LGMD, McArdle) in H1 2024; 3-month LYNX data (Duchenne) in H1 2024.","EDG-7500 Phase 1 data in healthy volunteers and oHCM patients expected Q3 2024.","Terminated ATM equity program with BofA Securities; no further sales under existing prospectus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264236,"accession_number":"0001157523-23-001700","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Q3 net loss $25.7M; starts pivotal GRAND CANYON study for EDG-5506","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents ~$290M; Q3 net loss $25.7M ($0.41/share) vs $21.5M prior quarter.","Initiated GRAND CANYON, global pivotal study of EDG-5506 in Becker MD, aiming for ~120 patients.","LYNX Phase 2 trial for Duchenne expanding with new cohort; interim data expected H1 2024.","Phase 1 trial of EDG-7500 for hypertrophic cardiomyopathy under way; Phase 1b planned H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281481,"accession_number":"0001157523-23-001312","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise reports Q2 2023 net loss $21.5M; positive ARCH 12-month data for EDG-5506","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $310M as of June 30, 2023.","R&D expenses $19.6M, G&A $5.8M; net loss $0.34 per share.","ARCH study: CK reduced 37% (p=0.001), fast skeletal troponin I reduced 79% (p<0.0001) at 12 months.","GRAND CANYON pivotal cohort for Becker expected to start enrollment in 2H 2023; ~120 patients.","Phase 1 trial of EDG-7500 for HCM expected to start in 2H 2023, subject to IND clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281480,"accession_number":"0001104659-23-081202","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2023-07-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Edgewise receives Nasdaq notice for audit committee non-compliance; cure period until June 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice on July 10, 2023 from Nasdaq: audit committee fell below 3 members after Dr. Kenneth Harrison resigned from board and audit committee on June 19, 2023.","Cure period: until earlier of next annual shareholders' meeting or June 19, 2024; if annual meeting before Dec 18, 2023, then compliance needed by Dec 18, 2023.","Company intends to rely on cure period and is evaluating board and committee composition to regain compliance.","Failure to cure could result in delisting; company may appeal to a Hearings Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300297,"accession_number":"0001104659-23-073465","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Director Kenneth Harrison resigns from Edgewise board; company to cure Audit Committee vacancy under Nasdaq rules","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kenneth Harrison, Ph.D. resigned from Board and all committees effective June 19, 2023; not due to disagreement.","Resignation leaves Audit Committee with fewer than three members, violating Nasdaq Listing Rule 5605(c)(2)(A).","Company notified Nasdaq on June 21, 2023 and will use cure period under Rule 5605(c)(4)(B) to regain compliance.","Edgewise is evaluating board and committee membership to fill vacancy and restore compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300296,"accession_number":"0001104659-23-072232","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Edgewise Therapeutics enters $125M ATM offering with BofA, terminates Cowen agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters Sales Agreement with BofA Securities for at-the-market offering of up to $125M in common stock.","BofA will receive up to 3.0% of gross proceeds from shares sold under the agreement.","Prior ATM agreement with Cowen terminated on June 15, 2023; no shares were sold under that agreement.","Company may sell shares from time to time, with no obligation to sell; can suspend or terminate at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300295,"accession_number":"0001104659-23-070064","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Edgewise Therapeutics shareholders elect three Class II directors, ratify KPMG as auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Laura Brege reelected with 47,325,534 votes for, 11,602,125 withheld; broker non-votes 1,064,399.","Badreddin Edris reelected with 45,321,337 for, 13,606,322 withheld; broker non-votes 1,064,399.","Jonathan Root reelected with 45,595,269 for, 13,332,390 withheld; broker non-votes 1,064,399.","Ratification of KPMG as independent auditor passed with 59,989,284 for, 2,555 against, 219 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300294,"accession_number":"0001157523-23-000822","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Therapeutics reports Q1 2023 net loss of $22.8M; cash at $328M; advancing EDG-5506 and EDG-7500 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.8M ($0.36 per share) vs $19.4M in prior quarter; R&D spend rose to $19.9M.","Cash, cash equivalents and marketable securities of $328M as of March 31, 2023.","Advancing Phase 2 CANYON (BMD) and LYNX (DMD) trials for EDG-5506; interim DMD data expected Q4 2023.","IND-enabling studies for EDG-7500 (HCM) ongoing; Phase 1 start expected in 2H2023.","Plan to add registration-enabling cohort in CANYON in 2H2023; 12-month ARCH data expected Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320332,"accession_number":"0001104659-23-029022","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Edgewise Therapeutics appoints Dr. Jonathan Fox to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jonathan Fox appointed as Class III director, term expiring at 2024 annual meeting.","He is President and CMO of BridgeBio Pharma and former CMO of MyoKardia, inventor of Camzyos.","Compensation includes $38k annual cash retainer, $4k for Nominating Committee, and stock option with ~$300k grant date fair value.","Company plans to advance EDG-7500 towards Phase 1 trial in HCM in H2 2023.","No arrangements or transactions requiring disclosure under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320331,"accession_number":"0001157523-23-000343","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise reports Q4 2022 net loss $19.4M; cash $352M; advancing EDG-5506 and EDG-7500 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $352M as of Dec 31, 2022.","Q4 2022 net loss $19.4M ($0.31 per share); R&D expenses $16.6M, G&A $5.5M.","EDG-7500 for HCM entered IND-enabling studies; Phase 1 start expected 2H2023.","LYNX Phase 2 DMD trial interim data expected Q4 2023; ARCH BMD 12-month data Q2 2023.","CANYON BMD trial to be amended with potentially registration-enabling cohort in 2H2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338481,"accession_number":"0001157523-22-001506","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Q3 net loss $17.5M ($0.34/shr); cash $365M; EDG-5506 shows biomarker reductions","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $365M as of Sept 30, 2022; underwritten offering raised $129M net.","Net loss $17.5M ($0.34 per share) vs $16.1M ($0.32) prior quarter; R&D spend $13.9M.","Positive 6-month ARCH interim data: CK reduced 39%, fast skeletal troponin I reduced 75% in BMD adults.","CANYON Phase 2 trial in BMD (n≈66) and LYNX Phase 2 trial in DMD (n≈27) both advancing; no approved treatments.","EDG-002 preclinical program targets hypertrophic cardiomyopathy; IND-enabling studies planned for 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355845,"accession_number":"0001104659-22-100078","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2022-09-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Edgewise Therapeutics announces public offering of 11.6M shares at $10.32/share, expected gross proceeds $120M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten 11,627,907 shares; underwriters have 30-day option for additional 1,744,186 shares.","Public offering price $10.32/share; underwriters purchase at $9.70/share.","Expected gross proceeds of $120M before offering expenses; closing expected September 16, 2022.","Offering made via effective S-3 registration statement (333-264083); J.P. Morgan and SVB Securities as representatives.","Underwriting agreement includes customary representations, warranties, and indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355844,"accession_number":"0001104659-22-099487","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2022-09-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Edgewise announces FDA authorization for Phase 2 DMD trial; positive ARCH interim data in BMD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA authorized Phase 2 LYNX trial of EDG-5506 in children with DMD; dosing expected Q4 2022.","ARCH interim data: NSAA improved 1.17 points vs natural history decline of 1.22/year.","CK reduced 29% and fast skeletal muscle troponin I reduced 74% after 4 months.","9 of 12 BMD participants showed improvement or no decline on NSAA; no serious AEs observed.","EDG-5506 well-tolerated with no discontinuations; all patients dose escalated to 20 mg daily."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355843,"accession_number":"0001157523-22-001032","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise reports Q2 net loss $0.32/sh; positive EDG-5506 BMD interim data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $248.4M as of June 30; expected to fund operations through end of 2024.","Net loss $16.1M ($0.32/sh) for Q2 2022 vs $14.7M ($0.30/sh) prior quarter.","ARCH study: CK reduced 30%, TNNI2 reduced 68% after 2 months of EDG-5506 10 mg daily.","Enrolling CANYON Phase 2 trial of EDG-5506 in BMD; plan to start Phase 2 in DMD in 2022.","Preclinical EDG-002 program for HCM advancing; IND-enabling studies planned in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374127,"accession_number":"0001104659-22-074310","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2022-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Edgewise Therapeutics announces 2022 Annual Meeting voting results; two directors elected, KPMG ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kenneth Harrison, Ph.D. elected with 37,108,884 votes for and 6,977,766 withheld (1,496,573 broker non-votes).","Alan Russell, Ph.D. elected with 36,943,573 votes for and 7,143,077 withheld (1,496,573 broker non-votes).","Ratification of KPMG LLP as independent auditor passed with 45,582,421 votes for, 614 against, 188 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374126,"accession_number":"0001157523-22-000612","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Therapeutics reports Q1 2022 net loss of $14.7M; cash at $265.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.7M ($0.30 per share) vs. $12.7M in the prior quarter.","Cash, equivalents and marketable securities of $265.8M; expected to fund operations through 2024.","Completed enrollment of ARCH open-label study of EDG-5506 in BMD; Phase 2 trials planned for 2022.","R&D expenses $11.1M, up $2.0M from prior quarter; G&A flat at $3.7M.","Advanced preclinical EDG-002 program targeting hypertrophic cardiomyopathy; IND-enabling studies in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392733,"accession_number":"0001157523-22-000251","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise reports Q4 2021 net loss $12.7M, cash $281M; EDG-5506 Phase 1b positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2021 $12.7M ($0.26/share); full year net loss $42.8M ($1.14/share).","Cash, equivalents & marketable securities $281M as of Dec 31, 2021.","Phase 1b EDG-5506 in BMD: CK reduced 71%, TNNI2 reduced 83%; well-tolerated.","Phase 2 trials planned: BMD in H1 2022, DMD in H2 2022; ARCH open-label study ongoing.","R&D expenses $32.2M in 2021 (vs $15.0M in 2020); G&A $11.0M (vs $2.2M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392732,"accession_number":"0001157523-22-000027","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2022-01-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Edgewise reports positive Phase 1b results for EDG-5506 in Becker MD: biomarkers reduced 71-83%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EDG-5506 well tolerated with no serious adverse events; dizziness was mild and transient.","CK reduced 71% and TNNI2 reduced 83% after two weeks, near healthy volunteer levels.","Plasma and muscle exposures exceeded pharmacologically active levels from preclinical models.","No effect on voluntary grip, shoulder, or hip strength; ARCH open-label study enrolling.","Management webcast today at 9 a.m. ET to discuss findings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411126,"accession_number":"0001157523-21-001387","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise reports Q3 net loss $12.9M; positive Phase 1 MAD data for EDG-5506","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $290M as of Sept 30, 2021.","R&D expenses $9.9M (Q3 2021) vs $3.2M (Q3 2020), increase due to Phase 1 trial and headcount.","Net loss $12.9M ($0.26/share) compared to $3.6M in Q3 2020.","Positive EDG-5506 Phase 1 MAD topline: well tolerated, target engagement, no effect on voluntary strength or cardiac myosin.","First BMD patients dosed in Phase 1b; Phase 2 trials in BMD and DMD expected to start in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411125,"accession_number":"0001157523-21-001266","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2021-10-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Edgewise reports positive Phase 1 MAD results for EDG-5506; Phase 2 in BMD and DMD planned for 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EDG-5506 generally well tolerated; no serious adverse events; mild dizziness/somnolence resolved.","PK data showed muscle concentrations well above efficacious levels from preclinical DMD models.","PD demonstrated dose-proportional inhibition of involuntary twitch without affecting voluntary strength or cardiac myosin.","Phase 1b dosing of BMD patients initiated; Phase 2 in BMD expected Q1 2022, DMD H2 2022.","Follow-on open-label study in BMD planned for Q1 2022 to assess biomarkers over 3 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429872,"accession_number":"0001157523-21-001027","cik":1710072,"company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","form_type":"8-K","filed_at":"2021-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edgewise Therapeutics Q2 net loss $10.4M; cash $299M; EDG-5506 advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.4M ($0.21 per share) for Q2 2021, up from $4.0M loss in Q2 2020; R&D expenses $7.9M.","Cash and marketable securities of $299M as of June 30, 2021, funding pipeline through key milestones.","EDG-5506 Phase 1 MAD study ongoing; topline data from healthy volunteers and Becker patients expected late 2021.","Preclinical EDG-002 cardiac modulator for hypertrophic cardiomyopathy progressing with encouraging data."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3675377319.9856887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}